Medication helps, but you still lose track of meetings, struggle to start tasks, or finish the day with too much left undone. Looking for another option makes sense. Repetitive transcranial magnetic stimulation, or rTMS, may come up in that search.
I think rTMS is worth studying for ADHD, but the evidence is mixed. Some studies report improvements in ADHD symptoms or attention tests; others find no clear benefit for overall symptoms compared with sham stimulation. We need to consider both findings.[1][2]
Can rTMS help when medication is not enough?
rTMS uses a coil outside the head to generate magnetic pulses that induce electrical fields in the brain. Treatment does not involve surgery and differs from electroconvulsive therapy. Its effects depend on the stimulation protocol.[5]
For ADHD, it remains an intervention with limited and mixed evidence. A finding in another condition cannot establish its effectiveness for ADHD. Before considering it, identify what remains difficult and whether the diagnosis and current treatment need review.
If you are still exploring a possible diagnosis, read about adult ADHD and procrastination or try the ASRS screening questionnaire. A screening score does not establish a diagnosis.
Why do researchers target the prefrontal cortex?
Prefrontal networks contribute to attention and behavioural control. The right dorsolateral prefrontal cortex, or right DLPFC, is one target studied in ADHD.[1][2]
A plausible brain mechanism is a starting point for research. It does not tell us which individual will benefit, or establish the best location and dose. Subgroup findings should be treated as leads to investigate rather than a personalised treatment formula.
ADHD symptoms: positive findings and negative findings
A review published online in 2025 and in a 2026 journal issue included seven rTMS RCTs and 26 tDCS RCTs, with 1,049 participants across both interventions. That total is not the sample size of the rTMS trials alone. Its rTMS analyses reported benefits for inattention, hyperactivity/impulsivity and attention-related function.[1]
A 2024 meta-analysis of six sham-controlled trials, involving 169 participants, found no statistically significant benefit for overall ADHD symptoms. It did find improvement in inattention, but not in hyperactivity or impulsivity.[2]
| Review and outcome | Finding | What it suggests | What it cannot establish |
|---|---|---|---|
| 2025: inattention | g = -1.44; p = .002 | A positive symptom signal | An individual response rate |
| 2025: hyperactivity/impulsivity | g = -0.95; p = .005 | Benefit in that analysis | Agreement across reviews |
| 2024: overall symptoms | SMD = -0.24; p = .17 | No clear advantage over sham | Proof of no possible benefit |
| 2024: inattention | SMD = -0.76; p = .0002 | Possible benefit in one domain | Recovery across daily life |
Sources: references 1 and 2. The 2025 label refers to online publication. Standardised effect sizes are group differences, not percentages cured.
Attention tests, processing speed and everyday function
A 2023 meta-analysis included five RCTs with 189 participants across adult and child/adolescent populations. Sustained attention and processing speed improved, while memory and executive function did not show statistically significant benefits.[3]
| Cognitive domain | Result | Ability being tested | Practical limitation |
|---|---|---|---|
| Sustained attention | SMD 0.54; 95% CI 0.22–0.86 | Staying attentive over time | Not a 54% gain in productivity |
| Processing speed | SMD 0.59; p = .002 | Speed on information-processing tasks | Not proof of better decisions |
| Memory | No significant benefit | Retaining and retrieving information | No established benefit for forgetfulness |
| Executive function | No significant benefit | Planning and control | No promise of resolving procrastination |
Source: reference 3.
The sample sizes reported in the paper and forest plot do not match. The plot’s group totals add to 158, whereas the paper’s sustained-attention results paragraph states 149; the abstract gives 189 for the review overall. Outcome samples can differ from total review samples, but that does not resolve the 149-versus-158 discrepancy. The effect estimate is reported here without assigning a single verified sample size to that outcome.[3]
Why do reviews disagree?
Age, stimulation protocols, concurrent medication, comparison groups and outcome measures differ. Reviews can also reuse the same small trials. Several reviews do not necessarily represent several independent bodies of evidence.
Positive right-prefrontal subgroup findings do not establish superiority over every other target. A 2025 network meta-analysis adds comparisons, but uncertainties remain. There is no established universal ADHD stimulation schedule to promise every patient.[2][6]
Adult and paediatric findings need separate interpretation
This article focuses on adults. Some cited research includes younger participants, and findings cannot be transferred automatically between age groups. Nor does a trial adding stimulation to atomoxetine establish the same result for rTMS alone. Treatment decisions for children need their own assessment of development, safety, alternatives and ability to participate.[3]
Safety and its place in ADHD care
Headache and scalp discomfort can occur. Seizures are uncommon but require risk assessment, and appropriate hearing protection is needed. Discuss seizure history, relevant implants, medication changes and sleep deprivation with the treating team.[5]
Established adult ADHD care includes medication, environmental adjustments and ADHD-focused psychological interventions. NICE recommends considering structured psychological support, potentially including CBT, when medication is declined, poorly tolerated or insufficient. rTMS does not currently have evidence establishing it as an equivalent replacement.[4]
| Approach | Main purpose | Current role | Questions to discuss |
|---|---|---|---|
| Medication | Reduce core symptoms | Established option | Benefit, tolerability and monitoring |
| ADHD-focused psychological care | Address functional difficulties | Consider alone or alongside medication | Work, organisation and behaviour |
| Environmental adjustments | Reduce everyday demands | Part of comprehensive care | Reminders, tasks and routines |
| rTMS | Explore symptom and cognitive benefit | Evidence remains limited | Uncertainty, cost and outcome targets |
Sources and clinical synthesis: references 1–5. See the ADHD condition and treatment page for further discussion.
Frequently asked questions
Can rTMS replace ADHD medication?
Current evidence does not support routinely replacing medication with rTMS. If treatment is disappointing, review the diagnosis, formulation, use, adverse effects and coexisting difficulties before deciding what to change.[2][4]
Can I stop medication when starting rTMS?
Do not change prescribed treatment on your own. Agree on a plan with your clinician. Changing several treatments at once can also make it harder to tell what caused an improvement or deterioration.
How many sessions are needed?
No single session count is established for all people with ADHD. Ask how progress will be measured and when an ineffective course would be reconsidered. A research protocol is not a personal guarantee.[1][2]
How long do benefits last?
Evidence does not justify promising permanent benefit or a reliable duration for an individual. Short-term test performance and sustained everyday function need separate follow-up.[2][3]
What if I also have depression?
Assess the treatment goals separately. If rTMS is being considered for depression, discuss that indication on its own merits. Better concentration after mood improves does not by itself establish a direct effect on ADHD. Read more about rTMS and treatment-resistant depression.
Dr. Tam Win Hong’s perspective
I would start with the problem you want to change: missing information in meetings, finishing work only after an exhausting night, or planning far more than you can complete.
A better test score matters, but it may not answer that question. Before starting a treatment, agree on a practical target, the time and cost involved, and what happens if it does not help.
I’m interested in what rTMS might offer for ADHD, but the findings are still preliminary. A new option needs careful evaluation, and its arrival is no reason to overlook treatment that is already helping you.
References
- Chen Q, Pan N, Long Y, et al. Noninvasive Brain Stimulation in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Treatment Efficacy and Targeting Strategies. J Am Acad Child Adolesc Psychiatry. 2026;65(3):369–391. Epub 2025 Jul 21. DOI. PubMed.
- Chen CM, Liang SC, Sun CK, Cheng YS, Hung KC. A meta-analysis of randomized sham-controlled trials of repetitive transcranial magnetic stimulation for attention deficit/hyperactivity disorder. Braz J Psychiatry. 2024;46:e20233428. DOI. PubMed.
- Chen YH, Liang SC, Sun CK, et al. A meta-analysis on the therapeutic efficacy of repetitive transcranial magnetic stimulation for cognitive functions in attention-deficit/hyperactivity disorders. BMC Psychiatry. 2023;23:756. DOI / Full text. PubMed.
- National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline NG87. Recommendations. Accessed October 28, 2026.
- Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021;132(1):269–306. DOI. PubMed.
- Liang X, et al. Comparative efficacy of non-invasive brain stimulation for attention-deficit/hyperactivity disorder: a systematic review and network meta-analysis. Front Neurol. 2025;16:1650154. DOI. PubMed.